Physician profile
Donald Dworek
NPI 1760764476
$37,511.69
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $18K · 2021: $12K · 2022: $6,354.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15,352.22 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $8,789.63 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $6,316.05 | 2022 | |
| Abbvie INC. | $6,314.32 | 2021-2022 | |
| Medtronic USA, INC. | $591.75 | 2019 | |
| Genzyme Corporation | $69.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.64 | 2019 | |
| Eisai INC. | $22.52 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Dworek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.